Metadata supporting the article: On the clinical implications of systemic and local immune responses in human angiosarcoma
Creators: name: CHAN, Jason Yongsheng
name: TAN, Grace Fangmin
name: YEONG, Joe
name: ONG, Chee Wee
name: NG, Dave Yong Xiang
name: LEE, Elizabeth
name: KOH, Joanna
name: NG, Cedric Chuan-Young
name: LEE, Jing Yi
name: LIU, Wei
name: WONG, Ru Xin
name: Chin-Ann Johnny ONG
name: FARID, Mohamad
name: TEH, Bin Tean
name: Khee Chee SOO
Publisher: name: figshare
Year: 2021
Subjects: subject: 69999 Biological Sciences not elsewhere classified
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Biological Techniques
subject: Cancer
subject: 60405 Gene Expression (incl. Microarray and other genome-wide approaches)
subject: 111203 Cancer Genetics
subject: FOS: Clinical medicine
subject: FOS: Clinical medicine
subject: Biomarkers
subject: Medicine

description: Angiosarcomas are a rare subtype of soft-tissue sarcomas which exhibit aggressive clinical phenotypes with limited treatment options and poor outcomes. In this study, the authors investigated the clinical relevance of the peripheral blood neutrophil-to-lymphocyte ratio (NLR) as a marker of systemic immune response, as well as its correlation with intra-tumoral immune profiles in a subgroup of cases (n=35), using the NanoString PanCancer IO360 panel and multiplex immunohistochemistry.<br><b>Data access</b>: The NanoString gene expression profiling data generated during the current study, are available in Gene Expression Omnibus: <b>https://identifiers.org/geo:GSE162370</b>. All other datasets generated and analysed during the study (including pathologist scores of the multiplex immunohistochemistry/immunofluorescence images and survival data), are not publicly available to protect patient privacy, but will be made available from the corresponding author on reasonable request. For data access requests, please contact Dr. Jason Yongsheng Chan, Division of Medical Oncology, National Cancer Centre Singapore, email address: <b>jason.chan.y.s@nccs.com.sg</b>. <br><b>Study approval and patient consent</b>: Written informed consent for use of biospecimens and clinical data were obtained in accordance with the Declaration of Helsinki. This work was done under approval from the SingHealth Centralized Institution Review Board (CIRB 2018/3182).<b><br></b><b>Study aims and methodology: </b>Regardless of etiology or anatomical origin, angiosarcomas are characterized by a challenging clinical course with limited treatment options and dismal prognosis. Contemporary treatment of localized angiosarcoma often involves surgical resection with wide margins, with or without adjuvant radiotherapy. In the metastatic setting, chemotherapeutic agents including paclitaxel, doxorubicin, or targeted agents are typically administered, although this is often met with rapid drug resistance. More recently, responses to checkpoint immunotherapy in chemorefractory angiosarcomas have generated interest to better characterize their immune microenvironment, and its combination with chemotherapy is currently under investigation in prospective clinical trials.In this study, the authors performed a retrospective analysis of angiosarcoma patients in an Asian tertiary cancer center, reviewing their clinical features, treatment outcomes and prognosis. Simultaneously, the systemic immune responses as well as intra-tumoral immune-oncological signaling pathways were examined and their clinical relevance explored.One hundred and fifty patients diagnosed with histologically-proven angiosarcoma at the Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) between January 2000 and January 2020 were identified. All of the cases were reviewed by certified pathologists and the diagnoses were supported by immunohistochemical staining for vascular markers such as CD31 and/or ERG. Kaposi sarcoma, epithelioid hemangioendothelioma and intimal sarcoma were excluded from the study. A total of 112 patients with existing peripheral blood neutrophil and lymphocyte counts at the time of diagnosis (prior to any therapy including surgery) and/or metastatic relapse were analysed. NanoString gene expression profiling was carried out on RNA derived from tumor tissue of 35 patients. Multiplex Immunohistochemistry/Immunofluorescence (mIHC/IF) was performed (n = 34) using an Opal Multiplex fIHC kit (Akoya Bioscience, Menlo Park,California, USA). For more details on the methodology, please refer to the related article.<br><b>Datasets supporting the findings of this study:</b>Dataset <b>Patient data.xlsx</b> is in .xlsx file format and supports figures 1-4, tables 1-5, supplementary tables 1-9 and supplementary figures 1-6. The data file includes pathologist scores of the multiplex immunohistochemistry/immunofluorescence images, patient clinical data, analysis of peripheral blood neutrophil-to-lymphocyte ratios, survival status and statistical analysis, and will be made available on request, as described in the data access section above.NanoString gene expression profiling data of human angiosarcoma samples, are available in Gene Expression Omnibus: <b>https://identifiers.org/geo:GSE162370</b>. Raw data are available in .<b>RCC</b> file format and processed data are available in <b>.txt</b> file format.<br>